Search

everythinglearnresearchcommunity

for

Search:↓

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.

5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.

Selective androgen receptor modulators (SARMs) are a promising type of drug for various health conditions due to their targeted actions.

5α-reductase inhibitors may lower the risk of death from bladder cancer.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

New compounds were made that block an enzyme linked to breast cancer better than existing treatments.

5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction and reduced sexual desire, sometimes lasting after stopping the drug.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

These medications for BPH have known risks and may have new side effects.

PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.

Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.

5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.

5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.

These medications for BPH have known risks and may have new side effects.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.

GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.

5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.

5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.

5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.

5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.